Timing of Indomethacin Administration for the Prevention of Post-ERCP Pancreatitis (PEP)

Timing of Indomethacin Administration for the Prevention of Post-ERCP Pancreatitis (PEP)

To determine if the timing of administration of indomethacin affects the primary outcome of post-ERCP pancreatitis (PEP). Patients undergoing ERCP will be randomly assigned to receive pre or post-procedure rectal indomethacin to prevent the occurrence of PEP.

Inclusion Criteria:

• All patients referred for ERCP at the University of Alberta
• Age greater than 18 years
• Ability to provide written informed consent

Exclusion Criteria:

• Acute pancreatitis
• Active peptic ulcer disease
• Rectal disease
• Aspirin-induced asthma
• Nonsteroidal anti-inflammatory drug (NSAIDs) induced hypersensitivity
• Pregnancy
• Breast feeding
• Creatinine clearance < 30 ml/min